4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by stock analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.
FDMT has been the subject of a number of other reports. Roth Capital cut their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. Chardan Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, 4D Molecular Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $30.40.
Read Our Latest Research Report on FDMT
4D Molecular Therapeutics Trading Up 11.2%
Shares of 4D Molecular Therapeutics stock traded up $0.93 during trading on Wednesday, reaching $9.25. The company's stock had a trading volume of 425,560 shares, compared to its average volume of 835,956. The stock has a 50-day moving average price of $6.89 and a two-hundred day moving average price of $4.80. 4D Molecular Therapeutics has a one year low of $2.23 and a one year high of $9.38. The stock has a market capitalization of $432.16 million, a P/E ratio of -2.63 and a beta of 2.93.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. As a group, sell-side analysts anticipate that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.
Institutional Trading of 4D Molecular Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in FDMT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of 4D Molecular Therapeutics by 7.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company's stock valued at $247,000 after purchasing an additional 2,925 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at approximately $99,000. Peapod Lane Capital LLC raised its holdings in shares of 4D Molecular Therapeutics by 35.3% in the first quarter. Peapod Lane Capital LLC now owns 195,853 shares of the company's stock valued at $633,000 after purchasing an additional 51,110 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in 4D Molecular Therapeutics during the first quarter worth $41,000. Finally, Proficio Capital Partners LLC increased its holdings in 4D Molecular Therapeutics by 26.0% during the first quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company's stock worth $75,000 after buying an additional 5,195 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.
About 4D Molecular Therapeutics
(
Get Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.